Lavender Muirhead
Family · Baytown, TXNPI 1700318508
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,025 of the $7,225 with a category attached, or 83.4%. It is spread thinly across 41 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,826 and has fallen 94.0% since, to $229 in 2024. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AstraZeneca$852
- Esperion Therapeutics, Inc.$526
- Gilead$329
- Eisai Inc.$293
- Johnson & Johnson$292
- plus $4K from 35 others
What the payments were for
- Consulting fees$1,20017%
- Food & beverage$6,02583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 4 | $1,236 |
| AstraZeneca(2 entities) | 17 | $852 |
| Esperion Therapeutics, Inc. | 9 | $526 |
| Gilead | 3 | $329 |
| Eisai Inc. | 19 | $293 |
| Johnson & Johnson | 5 | $292 |
| Bayer | 13 | $279 |
| GSK | 7 | $270 |
| AbbVie | 15 | $256 |
| Sanofi | 2 | $232 |
| SK Life Science, Inc. | 10 | $209 |
| Novo Nordisk | 19 | $199 |
| Scynexis, Inc. | 3 | $194 |
| Boehringer Ingelheim | 7 | $177 |
| Amarin Pharma, Inc. | 9 | $160 |
| Lilly USA, LLC | 8 | $143 |
| Stemline Therapeutics Inc. | 1 | $122 |
| Inspire Medical Systems, Inc. | 1 | $119 |
| Amgen | 7 | $116 |
| Pfizer | 9 | $115 |
| Merck | 6 | $107 |
| Abbott | 1 | $103 |
| Edwards Lifesciences | 1 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $100 |
| Idorsia Pharmaceuticals US Inc | 1 | $96 |
| Mylan Specialty L.p. | 1 | $94 |
| Neurocrine Biosciences, Inc. | 4 | $67 |
| Biogen | 4 | $61 |
| Coloplast | 2 | $54 |
| Avanir Pharmaceuticals, Inc. | 3 | $46 |
| Collegium Pharmaceutical, Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Novartis | 2 | $33 |
| GRT US Holding, Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Argenx US, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Optinose US, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- NEXLETOL$365
- NEXLIZET$365
- XARELTO$245
- FARXIGA$242
- FABRAZYME$232
- FASENRA$125
- BRILINTA$122
- Inspire$119
- UBRELVY$118
- TRELEGY ELLIPTA$113
- Kerendia$113
- JARDIANCE$112
- Vemlidy$104
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$103
- Edwards SAPIEN 3 Transcatheter Heart Valve$101
How this compares
$7,225 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,694 |
| Atorvastatin Calcium | 80 | $1,881 |
| Rosuvastatin Calcium | 24 | $1,375 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 13 | $830 |
| Pravastatin Sodium | 17 | $808 |
| Montelukast Sodium | 17 | $761 |
| Diclofenac Sodium | 31 | $580 |
| Omeprazole | 17 | $548 |
| Fluticasone Propionate | 39 | $520 |
| Pantoprazole Sodium | 17 | $509 |
| Lisinopril | 38 | $436 |
| Alendronate Sodium | 22 | $434 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $410 |
| Losartan Potassium | 35 | $395 |
| Azelastine Hcl | 11 | $352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $270 | $4,69412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Baytown
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.